You are here: Home » Current Affairs » Coronavirus » News
Business Standard

SEC meeting on full market approval for Covishield, Covaxin today: Report

SII had applied for market approval for the Covishield vaccine in December 2021 and Bharat Biotech has also applied for the same 10 days ago.

Topics
Coronavirus

ANI 

Covaxin, Covishield, serum institute of india, bharat biotech, vaccine, vaccination, coronavirus, covid

Drugs Controller General of India (DCGI)'s Subject Expert Committee will review applications of Bharat Biotech and Serum Institute of India (SII) for full market approval to Covaxin and Covishield respectively on Friday, sources said.

SII had applied for market approval for the Covishield vaccine in December 2021 and Bharat Biotech has also applied for the same 10 days ago.

Further, Bharat Biotech has informed that Covaxin is now a universal vaccine for adults and children. "Our goals of developing a global vaccine against COVID-19 have been achieved and all product development for licensure has been completed," it said.

However, both Covaxin and Covishield are currently authorized for emergency use only.

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) met on January 1 and January 2, 2021, and made recommendations in respect of the proposal for Restricted Emergency Approval of COVID-19 virus vaccines of Serum Institute of India and Bharat Biotech.

The SEC consists of domain knowledge experts from the fields of pulmonology, immunology, microbiology, pharmacology, pediatrics, internal medicine, etc.

It had reviewed the data on the safety and immunogenicity of the vaccine and recommended for grant of permission for restricted use in an emergency situation in the public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains. The clinical trial ongoing within the country by the firm will continue.

SII and Bharat Biotech vaccines have to be administered in two doses. All three vaccines have to be stored at 2-8 degrees Celsius.

After adequate examination, CDSCO had decided to accept the recommendations of the Expert Committee and accordingly, SII's Covishied and Bharat Biotech's Covaxin were approved for restricted use in an emergency situation.

Notably, the administration of Covaxin and Covishield began on January 16, 2021, in the country.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, January 14 2022. 13:53 IST
RECOMMENDED FOR YOU